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The aim of this report was to characterize osteonecrosis of the jaws (ONJ) in previously irra-
diated fields in dogs that underwent radiotherapy (RT) for oral tumors. Osteoradionecrosis
of the jaw (ORNJ) was further defined as osteonecrosis in a previously irradiated field in the
absence of a tumor.Thirteen dogs clinically diagnosed with 15 ONJ lesions were included in
this retrospective case series. Medical records were reviewed for: breed, sex, weight, and
age of the patient, tumor type, location in the oral cavity and size, location of the ONJ, time
from RT to ONJ onset, known duration of the ONJ, and tumor presence. Where available,
histological assessment of tissues obtained from the primary tumor, and tissues obtained
from the ONJ lesion, was performed, and computed tomographic (CT) images and dental
radiographs were reviewed. RT and other treatment details were also reviewed. Twelve
dogs developed ONJ in the area of the previously irradiated tumor or the jaw closest to the
irradiated mucosal tumor. Recurrence of neoplasia was evident at the time of ONJ diagno-
sis in five dogs.Time from RT start to ONJ onset varied from 2 to 44 months. In three cases,
ORNJ developed after dental extractions in the irradiated field. Dental radiographs mostly
revealed a moth-eaten pattern of bone loss, CT mostly revealed osteolysis, and histopathol-
ogy was consistent with osteonecrosis.To conclude, development of ONJ/ORNJ following
RT is a rare, but potentially fatal complication. Patients undergoing RT may benefit from a
comprehensive oral and dental examination and treatment prior to RT.
Keywords: dog, jaw osteonecrosis, oral tumors, osteoradionecrosis, radiotherapy
INTRODUCTION
Radiotherapy (RT) is an important treatment modality for oral
tumors in humans (1) and dogs (2–4); however, the irradiated
patient is susceptible to developing early and long-term com-
plications due to radiation (1–5). Osteoradionecrosis (ORN) of
the jaw (ORNJ) is a devastating long-term complication of RT in
humans that leads to reduced quality of life due to pain, dysphagia,
facial deformation, and may even result in death (1, 6–8). Several
theories about ORNJ pathogenesis have been suggested, with the
latest considering bone damage being caused by radiation-induced
fibrosis due to acute inflammation, production of free radicals,
and chronic activation of fibroblasts (1). The reported incidence
of ORNJ in humans ranges from 2 to 8% with a reported decline
in recent years (1, 6–8). Late complications of RT in dogs are
also rare (2), although the reported frequency of ORN is variable.
In appendicular sites, ORN was reported in 4% of cases treated
with orthovoltage RT in one study (9). However, Théon et al. (3,
4) reported that 6.4–7.6% of cases treated with megavoltage RT
for canine oral tumors experienced ORNJ. Although orthovolt-
age is rarely used in current veterinary RT, Thrall (10) reported
that 5% of dogs developed ORNJ after orthovoltage RT for canine
acanthomatous ameloblastoma (CAA).
The diagnosis of ORNJ in humans is based primarily on clinical
signs; usually ulceration of the mucosa with exposure of necrotic
bone is noted. However, additional definitions and classifications
have been employed, mainly depending on the persistence or
recurrence of a primary tumor, radiologic signs, duration of bone
exposure, and extent of the disease (1, 6, 11–13). Several fac-
tors predisposing a patient for ORNJ development have also been
described in human medicine (1, 6, 7, 14), but reports are rare in
veterinary medicine.
The aim of this retrospective study was to characterize
osteonecrosis of the jaws (ONJ) in previously irradiated fields in a
series of dogs that underwent RT for oral tumors as this entity is
poorly defined in the veterinary literature. ORN of the jaw (ORNJ)
was specifically defined for the purpose of this study as osteonecro-
sis in a previously irradiated field in the absence of persistent or
recurrent tumor.
MATERIALS AND METHODS
SELECTION CRITERIA
Medical records from the small animal clinic of the William R.
Pritchard Veterinary Medical Teaching Hospital of the University
of California Davis, were searched for dogs that had diagnostic
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and/or treatment procedures for clinically diagnosed ONJ based
upon clinical signs of ulceration of the mucous membrane with
exposure of necrotic bone, regardless of tumor presence or recur-
rence. Ten cases met the inclusion criteria and were included in
this study. Two additional cases were evaluated at Aggie Animal
Dental Center, Mill Valley, CA, USA, and one additional case at the
Department of Clinical Sciences, College of Veterinary Medicine,
Cornell University, resulting in a total of 13 cases included in this
study.
This investigation did not seek to identify the incidence of
ONJ/ORNJ lesions in previously irradiated fields. The cases series
reported here represent patients with ONJ/ORNJ who were seen
at three different veterinary dentistry and oral surgery referral
hospitals, regardless of where in the USA the cases were treated
with RT.
MEDICAL RECORDS REVIEW
Medical records were reviewed, and the following data were
recorded: breed, sex, weight, age of the patient at the start of RT,
tumor type, location in the oral cavity and size (T ) (15), location
of the ONJ, time from RT to ONJ onset, and known duration of
the ONJ. Time from RT to ONJ onset was determined as the time
interval between the start of the (first) RT fraction and the onset of
clinical signs typical of ONJ (ulceration of the mucosa with expo-
sure of necrotic bone). Additionally, tumor presence or recurrence
was recorded, and lesions where none was reported were consid-
ered “true” ORNJ (1). Known duration of the ONJ (i.e., duration
of bone exposure) was determined as the interval between lesion
identification (either by the client, referring veterinarian, or at the
referral hospital) to the time of healing following surgical interven-
tion, death, or last available follow-up. In cases, where the histology
slides were available for review, histological assessment of the pri-
mary tumor before RT and of the tissues obtained from the site
of the clinically determined ONJ, was performed. Additionally,
computed tomographic (CT) images, if available at initial presen-
tation (before RT) and at ONJ clinical diagnosis, were evaluated on
a medical grade flat-screen monitor with commercially available
software (eFilm Work station 3.4, eFilm Medical Inc., Toronto,
ON, Canada). Dental radiographs were also reviewed. Similarly,
RT details were also reviewed for information on radiation plan-
ning and delivery, and any additional treatments before and/or
during the RT were also recorded.
RESULTS
POPULATION
Over a 25-year period (1989–2014), 13 dogs were clinically diag-
nosed with 15 ONJ lesions in previously irradiated fields (Table 1).
Six dogs were mixed-breed, two were labrador retrievers, and one
each of the following breeds: golden retriever, beagle, bloodhound,
bichon frise, and brittany spaniel. There were five spayed females
and eight castrated males. Dogs ranged in weight from 12.6 to
40 kg (median 25.5 kg, mean 25.4 kg). Dogs were 8–17 years old
(median 11 years, mean 10.8 years) at the start of RT.
CHARACTERISTICS OF THE PRIMARY TUMOR
The dogs were treated for each of CAA (N = 4), squamous cell
carcinoma (SCC, N = 4), and melanoma (MM, N = 4), and for
an undifferentiated sarcoma (N = 1). Slides of the primary neo-
plastic lesions were available for review in only three cases, with
all other tumors diagnosed by outside commercial laboratories.
In the three cases with slides available, the neoplasia diagno-
sis was confirmed histologically by a board-certified pathologist
(BGM). Location and size of the oral tumors are presented in
Table 1.
Pre-RT imaging (dental radiographs, skull radiographs, and/or
CT) were available for six of the dogs (all T3 cases and one T2
case) and revealed bony invasion in three of the T3 cases. Data on
the size of the tumors were not available for two dogs.
For radiation treatments, patients were treated using a Cobalt-
60 (Co-60 unit) (El Dorado 8, AECL, Montreal, QC, Canada),
4 MV linear accelerator (Clinac 4, Varian, Palo Alto, CA, USA), or
Clinac 2100 (Varian, Palo Alto, CA, USA). The source used for
treatment of the Case 9 is unknown. Patients were treated with
32–54 Gy in 3–8 Gy fractions depending on the clinical radia-
tion plan. The total number of fractions delivered ranged from
3 to 17 fractions. A total of four patients were treated with a
palliative plan (4× 8 Gy on a once- or twice-weekly basis) for
gross CAA, MM, and SCC. A total of six patients were treated
with a more coarsely fractionated definitive protocol (7× 6 Gy
once weekly or 12× 4 Gy Monday–Wednesday–Friday) for CAA
and MM. Three cases were treated with more typical fraction-
ated definitive protocols (16× 3 Gy or 18× 3 Gy) for SCC and
undifferentiated sarcoma. One patient received both a coarsely
fractionated definitive protocol (12× 4 Gy), followed by a pal-
liative protocol 7 months later (Tables 2–4). Nine patients were
treated with a hand-calculated plan, while four patients received
a computer-based plan using 3D-conformal planning. Eleven
patients had gross disease visible at the time of RT treatment,
and three patients had gross disease noted in the record at the
end of RT (Table 1). Both of the dogs without gross disease
received definitive-intent radiation protocols, while those patients
with gross disease received either palliative or definitive-intent
protocols.
One patient had a treatment interruption of 13 days between
fractions seven and eight, and the eighth fraction was given as
a dose of 6 Gy; the reason is unknown. One patient received
only five out of six planned doses. One patient received its first
dose as a single field, after which the treatment was changed to
a parallel-opposed two-field technique for subsequent fractions;
the last treatment was not delivered due to poor patient condition.
One patient received 3 Gy on its first definitive treatment day, but
thereafter received 4 Gy fractions. The American College of Vet-
erinary Radiology-Radiation Oncology recommended reporting
data for radiation studies can be found in Tables 2–4 (16).
OTHER TREATMENTS
Prior to RT, three dogs had their oral masses surgically reduced,
including bone excision in one of these dogs. The other 10 dogs
received no surgical intervention (other than biopsy) prior to RT.
The stage of periodontal disease was not established in the majority
of cases before RT, but five dogs received full periodontal treatment
up to 3 months prior to initiation of RT.
Eleven dogs were treated with an antibiotic during or imme-
diately after RT, but the timing and antibiotic selected varied.
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Table 1 | General characteristics of the primary tumor and osteonecrosis lesion.
Case Tumor location Tumor
type
T stage Gross
tumor
disease
at RT
start
Gross
tumor
disease
at RT
end
Lesion
location
Imaging
of the
lesion
CT/dental
radiographs
Histopathology Time to lesion
onset
Known
lesion
duration
Tumor
recurrence
at lesion
onset
Outcome
1 L caudal maxilla
(P3–P4)
SCC T1 No No L caudal
maxilla
No/yes No 15.5 months,
post-extractions
1 month No Lost to follow-up
2 R buccal mucosa MM N/A Yes No R caudal
maxilla
No/no Yes – soft tissues
only
3.5 months,
post-extractions
3 months No Lost to follow-up
3 L caudal mandible
(M1, lingual)
CAA T1 Yes No R caudal
mandible
Yes/yes Yes 17 months 3 months No Remission after
mandibular rim excision
4 L caudal maxilla CAA T3b Yes No L caudal
maxilla
Yes/yes – at
the time of
ONJ revision
Yes – soft tissues
only
4 months 16 months No Stable disease after
several débridements
5 Hard-soft palate
junction
MM T2 No No L caudal
maxilla; later
R caudal
maxilla
Yes/yes;
yes/yes
Yes; yes – soft
tissues only
L side: 26 months
(9 months
post-extractions);
R side: 44 months
L side:
2 months;
R side:
1 month
No L side: remission after 2
débridements; R side:
remission after
débridement
6 L caudal oral
cavity/oro-pharynx
MM T3a Yes No L caudal
mandible
No/yes Yes – soft tissues
only
6 months 1.5 months No Progressive lesion,
euthanasia
7 Sublingual MM T1 Yes No L and R
caudal
mandibles
No/yes Yes – not available
for review
13 months <1 month No Lost to follow-up
8 R caudal maxilla SCC T1 Yes No R caudal
maxilla
No/yes Yes – not available
for review
3 months 2 months No Managed medically for
6 months prior to
euthanasia
9 R caudal mandible SCC N/A Yes No R caudal
mandible
Yes/yes No 2 months 1 month Yes Euthanasia suggested
10 L caudal maxilla
(P3-M2)
CAA T3b Yes Yes L caudal
maxilla
No/no No 13 months 6 months Yes Slowly progressive lesion,
euthanasia suggested
11 R caudal mandible
(M1–M3, crossing
midline)
SCC T3b Yes No R caudal
mandible
No/no No 6.5 months 1 month Yes Lost to follow-up
12 R caudal mandible
(P3–M1)
CAA T2 Yes Yes R caudal
mandible
Yes/yes Yes 11 months 3 months Yes (SCC) Remission after 2nd
resection (R rostral
mandibulectomy)
13 L caudal mandible Undiffer-
entiated
sarcoma
T3a Yes Yes L caudal
mandible
Yes/yes No 8.5 months 1 week Yes Euthanasia suggested
L, left; R, right; P, premolar tooth; M, molar tooth; SCC, squamous cell carcinoma; MM, melanoma; CAA, canine acanthomatous ameloblastoma; T1, tumor smaller than 20mm in maximum diameter; T2, tumor
20–40mm in maximum diameter; T3, tumor larger than 40mm maximum diameter (a, without bone involvement; b, with bone involvement).
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Table 2 | Reporting of radiation prescription and target doses as recommended by the American College of Veterinary Radiology-Radiation
Oncology (ACVR-RO).
Patient
number
RT intent Dose per
fraction (Gy)
Intended total
dose (Gy)
Prescription
point of dose
Target dose and dose
variation within plan
Number of
fractions
Time
schedule
1 Definitive 3 48 1 cm DMAX=3.11 Gy, exit
dose=2.59 Gy; treat to
100% isodose line
16 Daily
2 Coarsely fractionated,
definitive intent
6 42 3 cm Skin dose=6.9 Gy 7 Twice
weekly
3 Palliative 8 32 3 cm N/A 4 Weekly
4 Coarsely fractionated,
definitive intent
4 48 5 cm DMAX=4.86 Gy, Skin
dose=3.99 Gy
12 MWF
5 Coarsely fractionated,
definitive intent
4 48 PTV; normalize
to 90%
MIN for PTV: 78.3%; MAX
for PTV: 110.4%; mean for
PTV: 95.7%;
12 MWF
6 Coarsely fractionated,
definitive intent
4 48 depth 4 cm DMAX=4.58 Gy 12 MWF
7 Palliative 8 32 PTV; normalize
to 96.4%
100% to isocenter; MIN for
PTV: 85.9%; MAX for PTV:
103.5%; mean for PTV:
100.0%; modal 101.5%;
median 100.8%
4 Weekly
8 Palliative 8 32 5 cm Treat to 100% isodose line 4 Twice
weekly
9 Definitive 3 54 PTV; 100%
dose
DMAX=3.23 Gy, isocenter
dose=3 Gy
18 Daily
10 Coarsely fractionated,
definitive
intent+Palliative
7 months after
definitive
4 for definitive;
unknown for
follow-up
palliative
protocol
48 for definitive;
unknown for
follow-up
palliative
protocol
Record not
available
Record not available 12 for
definitive; 5
for palliative
MWF for
definitive;
twice
weekly for
palliative
11 Palliative 8 32 PTV; normalize
to 90%
For delivered plan: MIN for
PTV: 3.42 Gy; MAX for PTV:
18.2 Gy; Mean for PTV:
16.5 Gy; Range 3.24–18.2 Gy
3 delivered Weekly
12 Coarsely fractionated,
definitive intent
4 47 2.5 cm Skin 3.4 Gy, dmax 4.24 Gy 12 MWF
13 Definitive 3 48 PTV, normalize
to 88%
MIN for PTV: 29%; MAX for
PTV: 117.2%; mean for
PTV:109%
16 Daily
MWF,Monday,Wednesday, Friday treatment days; GTV, gross tumor volume; CTV, clinical target volume; PTV, planning target volume; DMAX, depth of dosemaximum;
MIN, minimum dose; MAX, maximum dose.
Only one dog received regular chlorhexidine gluconate oral rinses,
starting in the middle of the RT when mucositis developed. In two
dogs, a tea rinse was started at the time of mucositis development.
Three dogs received intratumoral chemotherapy (substance
unknown), and five additional dogs received systemic chemother-
apy, or a small molecule inhibitor (carboplatin, iniparib, or dox-
orubicin), or melanoma vaccine (Oncept, Merial) during RT or
shortly after the RT was completed.
Seven dogs were treated with prednisone, with the treatment
initiated during RT in six dogs and at the beginning of RT in one
dog. The use of analgesics varied, but typically included an opioid
and a non-steroidal anti-inflammatory drug in cases that were not
treated with a steroid.
CHARACTERISTICS OF THE ONJ LESIONS
Clinically, ONJ lesions were characterized as bone and soft tissue
necrosis of variable extent (1) (Figure 1), regardless of evidence
of tumor recurrence, and such lesions were detected in 13 cases.
Recurrence of neoplasia (Figure 2) was evident on clinical and/or
histopathological examination at the time of ONJ diagnosis in
five dogs. All other cases were considered to be consistent with a
diagnosis of ORNJ (Table 1).
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Table 3 | Reporting of radiation planning and target volumes as recommended by the ACVR-RO.
Patient
number
Plan
type
TPS
used
Heterogeneity
correction
GTV CTV PTV
1 Manual N/A N/A No gross tumor present Not defined Lmax P3–P4+3 cm
2 Manual N/A N/A Pinpoint lesion Not defined Not defined
3 Manual N/A N/A 1 cm mass Lmand M1 Not defined Not defined
4 Manual N/A N/A L caudal maxilla, eroded
L zygomatic bone, and
into L nasal cavity
Not defined Not defined
5 Computer Eclipse Yes Not defined Hard–soft palate junction, just L to the
midline, going caudally to 1 cm proximal
to the hyoid process
PTV=CTV+4 mm
Volume 9.52 cm3
6 Manual Eclipse N/A Lmand M1–M3 Not defined Lmand M1–M3+3 cm
7 Computer Eclipse Yes Not defined Not defined volume 31.1 cm3
8 Manual N/A N/A Not defined Not defined Not defined
9 Manual N/A N/A Not defined Not defined Not defined
10 Manual N/A N/A Record not available Record not available Record not available
11 Computer Eclipse No Not defined Rmand P4-ramus, with lateral and ventral
ST to midline. 158.19 cm3
PTV=CTV+3 mm,
volume=211.68 cm3
12 Manual N/A N/A 3 cm×2 cm×1.8 cm Not defined GTV+3 cm
13 Computer Eclipse Yes Not defined Left caudal mandible, level of P1–M3,
including ramus and tip of Max M1–M2,
with surrounding lateral soft tissue and
ventral soft tissue to midline; 66.96 cm3
PTV=CTV+1 cm
volume 192.33 m3
Co-60, Cobalt-60 radiotherapy unit; CTV, clinical target volume; PTV, planning target volume; TPS, treatment planning system.
As presented in Table 1, eight dogs developed lesions in the area
of the previously irradiated tumor. Four dogs developed ORNJ
lesion in the jaw adjacent to the irradiated tumor, and in one dog
the ORNJ was found on the contralateral mandible. In one dog
with a maxillary ORNJ lesion, an oronasal fistula (ONF) was noted
at presentation, and in two additional dogs ONF developed after
débridement. In two of these dogs, an orocutaneous fistula also
developed.
Time from RT to ONJ onset varied from 2 to 44 months
(median 9.8 months, mean 12.4 months), and for ORNJ specif-
ically 3 to 44 months (median 13 months, mean 14.7 months)
(Table 1). In one dog, ORNJ was noted 26 months after initia-
tion of RT and 9 months after dental extractions were performed
within the irradiation field; retained roots were later diagnosed.
The same dog later developed ORNJ of the contralateral maxilla.
Dental extractions were performed in the irradiated field in two
other animals, with subsequent development of ORNJ.
Known duration of the ONJ varied from 1 week to 16 months
(median 1.8 months, mean 2.9 months), and for ORNJ specifi-
cally from less than 1 to 16 months (median 2 months, mean
3.4 months) (Table 1).
Dental radiographs from the time of ONJ diagnosis were avail-
able for 10 dogs (11 ONJ/ORNJ lesions). With the exception of
one dog with bony changes in the area of the clinical lesion lim-
ited to horizontal bone loss associated with periodontitis, dental
radiographs consistently revealed a moth-eaten pattern of bone
loss (17). In six dogs, this moth-eaten bone loss was combined
with a geographic and/or permeative pattern of bone loss (17). In
three dogs where the mandible was involved, increased bone den-
sity with generalized loss of definition of the mandibular canal was
diagnosed, with a solid periosteal reaction (17) noted in one dog
(Figure 3). On CT, findings associated with the ONJ/ORNJ lesion
were described as extensive and incomplete or irregular osteolysis
(Figure 4) in five of six dogs, with one additional case demon-
strating diffuse thinning of the mandible with multifocal pitting
osteolysis (Figure 5).
Histopathology was performed in eight dogs with clinically
diagnosed ONJ/ORNJ lesions, but specimens were only avail-
able for review in six dogs, including a dog where two biopsies
of a progressive ONJ lesion were obtained 2 months apart. Bone
and soft tissues were available for evaluation in three dogs, and
only soft tissue was available for the other lesions. Soft tissue
changes in all but one dog included pleocellular inflammation
with mucosal hyperplasia and/or dysplasia and diffuse subepithe-
lial fibrosis with multifocal vasculopathy and thrombosis. In one
dog, the changes were most consistent with suppurative inflam-
mation associated with an extensive area of necrotic tissue, and
likely vascular thrombosis. Changes in the bone were described
as locally extensive osteonecrosis with bone resorption and osteo-
porosis (Figure 6). Two of these lesions demonstrated features
of osteomyelitis or had an attached biofilm on the exposed bone
surface. In one dog, recurrent CAA was confirmed at the time of
ONJ clinical diagnosis and was surgically removed with tumor-
free margins (segmental mandibulectomy). However, 2 months
later (13 months after the start of RT), the ONJ lesion was pro-
gressed and a right rostral mandibulectomy was performed. The
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Table 4 | Reporting of treatment delivery and beam information as recommended by the ACVR-RO.
Patient
number
Treatment
interruptions
Deviation
from
protocol
Beam
quality
and
energy
Equipment SSD/
SAD
Technique Beam
weighting
Field
size (cm)
Beam
modification
and bolus
Skin
bolus
1 No No 6 MV Clinac 2100 SSD Single field N/A 4.8×7.4 None 0.5 cm
bolus
2 No Reduced
field size to
4 cm×6 cm
for doses
#6–7
Co-60 Co-60 SSD Single field N/A 7×10 for 5
fractions,
4×6 for 2
fractions
Lead block in
front of
tongue. Gel
agent inside
cheek
None
3 No No 4 MV Clinac 4 SAD Parallel
opposed
Equal 5×8 None None
4 No No Co-60 Co-60 SSD Single field N/A 6×8 Pink bolus in
mouth and
superflab
between
gingiva and
lips
None
5 No No 6MV Clinac 2100 SAD Parallel
opposed
Equal 7.4×4.4 Mouth block;
MLC on 270°
beam
None
6 13-day break
between
fraction #7 and
#8
Fraction #8
and #9 given
at dose of
6 Gy after the
13-day break
4 MV Clinac 4 SSD Single field N/A 5.5×9.5 Wet gauze in
mouth
None
7 Not described Not
described
4 MV Clinac 4 SAD Parallel
opposed
Equal 3.6×11.5 Wedges (15°)
on both 0 and
180° beams
Not
described
8 Not described Not
described
4 MV Clinac 4 SAD Parallel
opposed
Equal 24×12 None None
9 No No 6 MV Clinac 2100 SAD Parallel
opposed
Equal 8×16 None 1 cm bolus
10 Only received
5/6 prescribed
palliative
doses
Record not
available
Co-60 Co-60 SSD Record not
available
Record not
available
Record not
available
Record not
available
Record not
available
11 Last treatment
not given
Changed
plan after 1st
fraction
6 MV Clinac 2100 SAD Single field
for first
fraction,
then
parallel
opposed
Equal 13.4×13.1;
then
11.4×8.4
First fraction:
MLC,
Subsequent
fractions: MLC
on both fields,
with wedge
(45°, left) on
210; mouth
block
1 cm on
angle 210
field
12 No First fraction
received 3 Gy
4 MV Clinac 4 SSD Single field N/A 6.5×4.5 None 0.5 cm
bolus
13 No 2 treatments
on same day
(fraction
11–12)
6 MV Clinac 2100 SAD 2 field: 90
and 275
beam
angles
1.5 (beam
angle 275),
0.5 (beam
angle 90)
9×13.1
and
8.9×13.1
Mouth block;
wedge
15°(right) on
90° beam
Wet gauze
0.5 cm
MV, megavoltage; SSD, source to surface distance; SAD, source to axis distance; MLC, multi-leaf collimator.
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FIGURE 1 | An intraoral photograph of the dog in dorsal recumbency
with ORNJ of the left maxilla (Case 5). There is an area of soft tissue
necrosis at the level of missing left maxillary first molar tooth with
underlying exposed necrotic bone covered partially by debris and hair. Note
also the severe abrasion of all remaining teeth.
histopathological evaluation of the right rostral mandible revealed
osteonecrosis and SCC, which was removed with tumor-free and
osteonecrosis-free margins. Review of the slides confirmed that
primary lesion was CAA and the later SCC. Since the time for
malignant transformation (5) was short, this may represent de
novo tumor development.
In three dogs (including one dog with two ORNJ sites),
the lesions healed after surgical intervention (one rim excision,
one segmental and later unilateral rostral mandibulectomy, two
débridement procedures). Two additional dogs received several
débridement procedures to remove all grossly non-vital tissue to
achieve stable or slowly progressive disease, or débridement was
combined with hyperthermia. One patient was managed medically
for 6 months prior to euthanasia. In one dog, progressive disease
required another débridement procedure, but the dog was eutha-
nized due to perioperative complications, and in another two dogs
euthanasia was suggested due to the extent of the disease and poor
quality of life. Four dogs were lost to follow-up.
DISCUSSION
The present study describes RT and associated treatments
employed in a series of 13 dogs treated for odontogenic or non-
odontogenic oral tumors. It further focuses on the characteristics
of the ONJ/ORNJ lesions that later developed, especially the site
of ONJ/ORNJ in relation to the primary tumor, time to onset,
and duration of the necrotic lesion, imaging, and histopathology
findings.
Radiotherapy alone can provide good tumor control in dogs
depending on tumor size and type (2–4), and local control and
survival time may be improved by combining RT with radiation
sensitizers, surgery, or chemotherapy (2). Some studies suggest
that chemotherapy use coincident with radiation may increase
the risk of ORNJ development (1, 7). Conventional definitive
RT in veterinary patients normally employs radiation fractions of
FIGURE 2 | An intraoral photograph of the dog in sternal recumbency
with ONJ of the right mandible (Case 9). There is an extensive area of
soft tissue necrosis with underlying exposed necrotic bone noted from the
distal root of the right mandibular first molar tooth to the level of missing
right mandibular third molar tooth. Note an uncomplicated crown fracture of
the right mandibular first molar tooth. There is a soft tissue mass noticeable
at the buccal aspect of the lesion, suggestive of neoplasia. Biopsy
confirmed recurrent SCC.
2–3.2 Gy once daily, 5 days a week, over 16–25 fractions (18). How-
ever, palliative RT protocols for veterinary patients have a wider
variety of dosing schemes, with fraction sizes of 4–9 Gy given over
a week or once weekly for 3–4 weeks being commonly used (19).
RT does induce changes in healthy cells and tissues, and both deter-
ministic and stochastic effects can occur (9). ORN is believed to
be a deterministic effect, where below a certain threshold dose no
effect is observed (9). In human patients, ORNJ is unlikely to occur
if the radiation dose delivered by conventional RT is below 60 Gy
(1, 6, 20). The risk of ORNJ in humans increases with the increased
radiation dose (1, 6, 20). It is notable that the protocols used for
RT in humans result in a much higher total dose to the tissue com-
pared to veterinary protocols that normally do not exceed 60 Gy.
Despite the lower total doses used in veterinary patients, ORN is
seen in patients receiving doses of 32–48 Gy. The evident ORN at
lower doses may be due to the higher dose per fraction (e.g., human
patients often receive doses <2 Gy (7) for definitive protocols com-
pared to veterinary patients that often receive 3–4 Gy for definitive
therapy, resulting in a similarly high biologically effective dose
despite the lower total dose delivered to dogs). Veterinary patients
who have gross disease at the time of RT may also have tumor
regression or tumor necrosis resulting in bone exposure, whereas
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FIGURE 3 | Intraoral radiograph, lateral view of the right (A) and left (B)
caudal mandible of the dog in Figure 2. (A) There is an extensive area (all
bone visible on the radiograph) of bony destruction, dominated by
combined moth-eaten and permeative patterns of bone loss on the right
mandible. Note also the generalized loss of definition of the mandibular
canal, with a solid periosteal reaction, most prominent at the level of the
distal root of right mandibular first molar tooth and missing right second
and third molar teeth. There is horizontal and vertical bone loss at the distal
root of the fractured right mandibular first molar tooth with furcation
involvement. (B) Radiograph of the healthy left mandible shows minor
horizontal bone loss at the mesial aspect of the left mandibular fourth
premolar tooth and second molar tooth. There is a crown fracture of the left
mandibular first molar tooth.
FIGURE 4 | Skull CT of the dog (Case 5) showing the section at the
level of maxillary molar teeth. There is extensive irregular osteolysis of
the right caudal maxilla, palatine bone, and the rostral aspect of the
zygomatic arch. There is remodeling of the caudal maxilla, palatine bone,
and rostral zygomatic arch on the left side, where previous osteonecrosis
was described (Figure 1). There is a missing left maxillary first molar tooth.
patients with a healthy mucosal lining after surgery tend to have
less bone exposure. This bone exposure could also contribute to
bone lysis, and infection. In human studies, Co-60 RT (6), high
FIGURE 5 | Skull CT of the dog (Case 3) showing the section at the
level of mandibular first molar teeth. There is a diffuse thinning and
multifocal pitting osteolysis of the cortical bone of the right mandibular
body, and the changes are most pronounced in the medial cortex.
total doses, short regimens using higher doses per fraction, and
large field sizes are all associated with an increased risk of ORNJ
(1, 20). Notably, the use of megavoltage RT results in reduced
frequency of ORNJ compared to lower-energy, orthovoltage ther-
apy (9). There is also evidence that continuous hyperfractionated
accelerated RT possesses less risk for ORNJ development, although
these protocols are not easily adapted to veterinary patients due
to anesthesia and time constraints, and deliver smaller fractions
to a low total dose (1, 7, 20). Definitive RT (without surgery) and
adjunctive RT pose similar risks of developing ORN in humans
(7). In this study, corticosteroid use during RT was employed to
reduce the RT-induced inflammation of the oral mucosa and skin
in seven of the dogs in this study. In a review looking at possi-
ble risks and predisposing factors, corticosteroids were found to
reduce the risk of ORNJ by 96% in humans (1).
Upon presentation, the dogs in the present study had lesions in
the oral cavity that were clinically described as soft tissue necrosis
of variable extent with underlying exposed necrotic bone, warrant-
ing a clinical diagnosis of ONJ or, specifically, ORNJ if no tumor
was noted (1). Although dogs <7 years of age were found to have a
significantly higher risk of ORN development at appendicular sites
in one study (9), all dogs in the present study were >8 years old. RT
may have been selected rather than surgery in these older dogs as a
less invasive treatment option, particularly for advanced, caudally
located tumors. In such cases, curative-intent surgical resection is
difficult or impossible; however, prolonged progression free inter-
vals following RT are reported in dogs with large odontogenic
tumors (3). The size of the tumors and degree of bone invasion
may also influence ORNJ development in humans (1), although
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FIGURE 6 | Regular (A) and polarized (B) histological image of the
specimen from the dog with an ORNJ lesion of the mandible (Case
3). (A) The alveolar bone comprises primarily lamellar, osteonal bone with
limited interstitial woven bone. The bone is necrotic, as evidenced by
diffuse, empty osteocyte lacunae, and attached basophilic to eosinophilic
biofilm (top of image). Multifocal, irregularly spaced, and shaped
resorption bays are present within the alveolar bone (clear
spaces/osteoporosis). Tooth dentin and a thin rim of cementum are
evident at the bottom of the image. These eosinophilic matrices are more
evident in the polarized image (B). A periodontal ligament is absent
between the cementum and adjacent alveolar bone, consistent with
ankylosis of the tooth.
our case series included both small (T1) and large (T2, T3) tumors
with and without bone involvement.
All but one of the ONJ/ORNJ lesions were found on the
site of tumor irradiation or in the jaw closest to the irradiated
tumor. Most human patients also develop ORNJ ipsilateral to the
tumor inside the radiation field. However, bilateral involvement
or involvement of the contralateral jaw may occur (21, 22), as also
noted in our cases. It is likely that the exit radiation dose con-
tributes to ORNJ in cases that develop bilateral or contralateral
ORNJ after receiving a single field of radiation. In cases receiv-
ing the common “parallel opposed” radiation technique, wherein
radiation beams are delivered from each side of the body, it is likely
that both the entrance and exit dose of the beams contribute to
development of ipsilateral, contralateral, or bilateral ORNJ lesions.
In humans, higher susceptibility of the mandible, and especially
the molar region, for ORNJ development is reported (1, 6, 7). Our
study had a similar pattern of caudal location, but site predilection
cannot be concluded from the present study.
The time to ORNJ onset varied greatly among dogs
(3–44 months after start of RT), which is similar (1–69 months)
to observations for mandibular ORN in humans (6). In human,
ORNJ typically develops during the first 4–36 months after RT;
the risk of developing ORNJ, however, remains for life (1). Because
dogs have a life span considerably shorter than that of humans, it is
difficult to project how long the risk of developing ORNJ remains
in the veterinary population.
None of the dogs in this study had undergone major surgery
before RT. Importantly, surgery performed immediately before RT
may increase the risk of ORN development in humans (7). In at
least three cases, however, ORNJ started after dental extractions.
Post-RT surgery, and especially dental extractions in the radiation
field, is considered one of the most important predisposing fac-
tors for ORNJ development in humans (1, 6, 14, 23), although
an incidence of only 2% per tooth extracted has been reported
(14). Reports in veterinary medicine are scarce, but dogs with
intranasal neoplasia that had surgery performed after accelerated
RT were more likely to develop ORN (24). It has been suggested
for human patients that comprehensive oral/dental examination
and dental extractions of all unrestorable or periodontally affected
teeth should be performed at least 7–10 days before RT, and ideally
3 weeks before RT to allow healing (1, 6–8, 23). However, protocols
for pre-RT dental evaluation have not been well established (7),
even though dental status of patients scheduled for RT treatment
may be poor (8).
Periodontal disease is a very common dental disease in middle-
aged to older dogs (25); however, routine oral and dental eval-
uation and dental treatment were not commonly performed in
the dogs included in this study. Ideally, oral/dental evaluation
and treatment should be performed prior to initiating RT. If
dental treatment is required during or after RT, surgical trauma
should be minimized and dogs receiving radiation to the oral
cavity, nasal cavity, or neighboring tissues should be managed
by experienced oral surgeons (23). Preoperative and postoper-
ative use of topical antiseptics and systemic antibiotics have also
been widely employed, but direct evidence that such medical treat-
ment reduces the incidence of ORNJ is currently lacking (14, 23).
Human studies suggest that oral hygiene should be maximized
during RT with the use of topical antiseptic mouthwashes (23);
these washes were rarely performed in the dogs reported in this
study.
The duration of bone exposure (1) may be very difficult to
determine in dogs because it may go unnoticed by the owner for
extended periods of time. This issue has also been debated in the
human literature, and some authors suggest that bone exposure
should be present for at least 1–3 months to prevent over diagnosis
of ORNJ (1, 12). With only a brief period of observation, a clini-
cian may erroneously diagnose ORNJ in a patient with mucositis
or mucosal radionecrosis with exposed but not necrotic underly-
ing bone (1). However, human ORNJ diagnostics suggest that if
radiographic changes in the bone are observed at the first visit, a
diagnosis of ORNJ can be made regardless of the period of bone
exposure (12).
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Imaging, including dental radiography and CT, can be very
useful to further investigate ORNJ lesions (1). Dental radiographs
of the lesions in advanced stages, when over 30% of bone min-
eral content is lost, usually reveal a mixed radiopaque/radiolucent
lesion, representing bone destruction (1) similar to the present
study. However, plain radiographs usually underestimate the
extent of damaged bone and do not correlate with the clinical
status (1, 12). A clear line of demarcation between devitalized
and vital bone may not be observed (1), which is in agreement
with the present report. CT has similar limitations (1) with the
earliest osseous imaging findings of ORNJ being cortical defects
and trabecular disorganization, air pockets, fractures, and seques-
tra formation in severely advanced lesions (21, 26). Even with
imaging, the diagnosis of osteonecrosis may still be difficult, and
its definition has been debated in human literature (1). During
surgery, bleeding bone can provide a helpful guide to defining
the extent of the necrosis (1), but histopathology is the ultimate
diagnostic tool to confirm osteonecrosis (1, 13, 27). Histopatho-
logical examination reveals changes typical of a hypovascular and
hypocellular/fibrotic tissue (1, 13, 27), which have been observed
in the present study. Importantly, histopathology is also needed to
rule out infection/osteomyelitis. In humans, microorganisms are
considered to play a minor role in the pathophysiology of ORNJ (1,
27), but they may cause a superimposed infection of ORNJ (21,
27). Also, histopathology is necessary to evaluate persistence or
recurrence of the neoplasia. In the present study, five dogs demon-
strated evidence of neoplasia, which may have contributed to the
osteonecrosis (1, 9).
Due to the retrospective nature of the study, certain limita-
tions exist. First, histopathological confirmation of osteonecrosis
was not available for all dogs. However, of the seven dogs lacking
histopathology review of the clinically diagnosed ONJ lesion, and
with an additional three dogs lacking bone in the samples, imag-
ing was available for six. In these cases, the imaging confirmed
bony involvement in five cases, supporting the clinical diagno-
sis of osteonecrosis (12). In one dog where no bony involvement
was seen radiographically, progressive disease was observed over
1.5 months without evidence of tumor recurrence, which was most
consistent with ORNJ. Also, of the 13 dogs included in this study,
6 had demonstrated evidence of tumor persistence or recurrence,
which likely contributed to the osteonecrosis.
CLINICAL RELEVANCE
The clinical consequences of ORNJ are significant, and treatment
may not always be possible due to the extent and severity of the
lesion. Although ORNJ appears to be a rare complication, clients
should be advised of possible development of ORNJ following RT.
In cases that are surgically amenable, especially smaller tumors,
surgery should be considered a first line treatment, as complete
removal of oral tumors can result in cure (28) with minimal effect
on function and appearance (29). In addition, with the develop-
ment of new reconstructive techniques (30), function and cosmesis
can often be preserved even with larger resections. Finally, until
with further studies we better understand ORNJ development in
animals, we suggest an oral exam and treatment to be performed
prior to RT for an oral tumor in dogs, as is the standard practice
in human medicine.
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